detecting neo-epitopes on tumour cells with unprecedented sensitivity
detecting epitopes from specific genetic constructs
detecting epitopes from therapeutic proteins for immunogenicity assessment
HLA-presented peptides represent the natural target of TCR T-cell therapies and TCR-mimic antibodies. Also when developing vaccines, knowledge of which antigen-derived peptides are presented on HLA complexes can be required.
Several approaches for the induction of tumor-specific T cells have been developed. If the desired peptides, but not undesired peptides are presented on a patient's HLA alleles are important quality and safety determinants. Alithea's CONZOOM technology is especially suited to answer these questions.
Therapeutic proteins such as antibodies, can be immunogenic in patients. This applies not only to protein therapeutics but also to CAR T constructs and any other gene therapy product that is translated to a protein.
Neoepitope-targeted therapies such as cancer vaccines and TCR-engineered T cell therapy are currently some of the most promising novel therapies.
Exact knowledge of which neoepitopes are presented by tumor cells are essential. Classical mass spectrometric strategies are limited by sensitivity or throughput and can rarely detect any neoepitopes.
Alithea’s NEOZOOM™ strategy was developed to increase sensitivity and detectability of neoepitopes and clearly outperforms classical strategies.
During target discovery and quality control of certain immunotherapies, it is of interest to idetify and quantify presentation of epitopes from specific genetic elements of interest.
Our CONZOOM™ technology allows to scan for gene- or construct-derived epitopes in high sensitivity and allows to optimally design follow-up experiments to profile T cell subsets by tetramers or ELISPOT assays.
A risk in the development of therapeutic proteins is the generation of high affinity anti-drug antibodies (ADA). After treatment with therapeutic proteins (Antibody, other protein drug and even CAR T-cells), it is possible that the patients' immune system responds to the drug and neutralizes it reducing efficacy of the treatment.
By assessing HLA-presented peptides, it is possible to study these immune processes. IMMZOOM allows for highly sensitive and reproducible detection of drug-derived antigens presented on HLA class II complexes.
Contact:
Alithea Bio UG (haftungsbeschränkt)
Liebühl 2A
79104 Freiburg im Breisgau
info(@)alithea-bio.com
IMPRINT - LEGAL NOTICE